Zusammenfassung
In Mitteleuropa sind die Trophoblasttumoren, insbesondere die malignen, sehr selten. Meist werden sie durch extrem hohe HCG-Werte und Metrorrhagien bzw. Abortsymptome entdeckt. Nach Diagnosestellung ist ein rasches, Bild gebendes Staging notwendig, um eine Metastasierung auszuschließen oder zu bestätigen. Trophoblasterkrankungen sind sehr chemosensibel. Deshalb stellt die Chemotherapie die wichtigste Therapieoption dar. In der Nachsorge ist die Überwachung des β-HCG essenziell.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Bagshawe K, Dent J, Webb J (1986) Hydatidiform mole in England and Wales 1973–1983. Lancet I: 673–677
Bagshawe K, Lawler S, Paradinas F, Dent J, Brown P, Boxer G (1990) Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet 335: 1074
Berkowitz R, Bernstein M, Laborde O, Goldstein D (1994) Subsequent pregnancy experience in patients with gestational trophoblastic disease. J Reprod Med 39: 228–232
Goto S, Ino K, Mitsui T et al. (2004) Survival rates of patients with choriocarcinoma treated with chemotherapy without hysterectomy: effects of anticancer agents on subsequent births. Gynecol Oncol 93: 529–535
Hoekstra A, Keh P, Lurain J (2004) Placental site trophoblastic tumor: a review of 7 cases and their implications for prognosis and treatment. J Reprod Med 49: 447–452
Knox S, Brooks S, Wong-You-Cheong J et al. (2002) Choriocarcinoma and epithelial trophoblastic tumor: successful treatment of relapse with hysterectomy and high-dose chemotherapy with peripheral stem cell support. Gynecol Oncol 85: 204–208
Köchli OR (1994) Staging der malignen Trophoblasterkrankungen: Ein Dilemma. Gynakol Geburtshilfe Rundsch 34: 3–6
Köchli OR, Schär G, Sevin BU et al. (1995) In vitro chemosensitivity of paclitaxel and other chemotherapeutic agents in malignant gestational trophoblastic neoplasms. Anti Cancer Drugs 6: 94–100
Li-Pai C, Shu-Mo C, Jian-Xuan F, Zi-Ting L (1995) PEBA regimen (cisplatin, etoposide, bleomycin, and adriamycin) in the treatment of drug-resistant choriocarcinoma. Gynecol Oncol 56: 231–234
Newlands E, Bagshawe K, Begent R, Rustin G, Holden L (1991) Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumors, 1979–1989. Br J Obstet Gynaecol 98: 550–557
Newlands E, Mulholland P, Holden L et al. (2000) Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental trophoblastic tumors. J Clin Oncol 18: 854–859
Ngan H (2004) The practicability of FIGO 2000 staging for gestational trophoblastic neoplasia. Int J Gynecol Cancer 14: 202–205
Seckl M, Fisher R, Salerno G et al. (2000) Choriocarcinoma and partial hydatidiform moles. Lancet 356: 36–39
Soper J, Evans A, Rodriguez G et al. (1995) Etoposide-platin combination therapy for chemorefractory gestational trophoblastic disease. Gynecol Oncol 56: 421–424
Woolas R, Bower M, Newlands E et al. (1998) Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome. Br J Obstet Gynecol 105: 1032–1035
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Köchli, O.R., Petru, E., Sevin, BU. (2005). Trophoblasttumoren. In: Praxisbuch Gynäkologische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30015-5_12
Download citation
DOI: https://doi.org/10.1007/3-540-30015-5_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-25667-0
Online ISBN: 978-3-540-30015-1
eBook Packages: Medicine (German Language)